The therapeutic time window for N-methyl-o aspartate (NMDA) antagonists, non-NMDA antagonists, and glutamate release inhibitors in focal models of isch emia appears to be about 1-2 h. In contrast, a free radical spin trap was found to have an improved therapeutic win dow. We compared the therapeutic time windows of the NMDA antagonist dizolcilpine maleate (MK-80l), the glutamate release inhibitor lamotrigine, and the free rad ical spin trap n-tert-butyl-a-(2-sulfophenyl)-nitrone (S PBN) against striatal lesions produced by the mitochon drial toxin malonate, which produces histotoxic hypoxia. Lamotrigine exerted neuroprotective effects when admin istered at I h before malonate injections. MK-801 pro tected at I h before and 1 h after malonate injections, BT (1993) Age-dependent striatal excitotoxic lesions pro duced by the endogenous mitochondrial inhibitor malonate.
A critical issue in treating cerebral ischemia is the time window in which one can administer the ther apy after insult and still achieve efficacy. There has been considerable debate as to the duration of the therapeutic time window based on results in animal studies. Most studies in models of either focal isch emia or excitotoxic lesions have suggested a maxi mal therapeutic window of 1-2 h (Foster et aI., 1988; Bakker and Foster, 1991; Massieu et aI., 1993; Park and Hall, 1994) . More recent studies in models of global ischemia, however, suggested that some compounds may exert efficacy when administered as long as 12-24 h after an ischemic insult (Li and whereas S-PBN showed efficacy when administered up to 6 h after malonate injections. Striatal injections of mal onate produced a rapid increase in lactate production and early changes in diffusion-weighted imaging as assessed by magnetic resonance imaging. Therefore, the time course to evolve a lesion in our model of histotoxic hyp oxia is comparable with that of other models of focal ischemia. These findings' provide direct evidence that a free radical 'Spin trap has an improved therapeutic win dow compared to an NMDA antagonist and a glutamate release inhibitor. This could be a therapeutic advantage in the treatment of clinical stroke patients. Key Words: Ex citotoxicity-Free radicals-Ischemia-N-Methyl-o aspartate-Stroke. Buchan, 1993; Sheardown and Suzdak, 1993) . Par ticularly intriguing was a recent report that admin istration of the free radical scavenger phenyl-N tert-butylnitrone could exert neuroprotective ef fects in a model of focal cerebral ischemia when administered as long as 12 h after the insult (Cao and Phillis, 1994) .
In the present study we examined the therapeutic time window of several neuroprotective compounds against striatal lesions produced by the mitochon drial toxin malonate, which produces histotoxic hypoxia. Malonate produces lesions that are similar to those of focal ischemia in many respects. The lesions are associated with partial metabolic com promise and they are attenuated by N-methyl-o aspartate (NMDA) antagonists, glutamate release inhibitors, and free radical scavengers (Beal et aI., 1993; Greene et aI., 1993; Henshaw et aI., 1994; Schulz et aI., 1995) . In the present study we there fore compared the therapeutic time window of the NMDA antagonist dizolcilpine maleate (MK-80l), the glutamate release inhibitor lamotrigine, and the free radical scavenger n-tert-butyl-a-(z-sulfonyl) nitrone (S-PBN).
MATERIALS AND METHODS
Male Sprague-Dawley rats (Charles River, Wilming ton, MA, U.S.A.) weighing 300-325 g were anesthetized with pentobarbital (50 mg/kg i.p.). MK-SOI (dizocilpine maleate) was obtained from Research Biochemicals (Wayland, MA, U.S.A.), and S-PBN from Aldrich (Mil waukee, WI, U.S.A.). Lamotrigine was a generous gift of Burroughs-Welcome (Research Triangle, NC, U.S.A.). Malonate (Sigma, St. Louis, MO, U.S.A.) was dissolved in distilled deionized water, and the pH was adjusted to 7.4 with 0.1 M HCI. Intrastriatal injections of 1.5 f.Ll con sisting of 3.0 f.Lmol of malonate were made in the left striatum as described previously (Beal et aI., \993). MK SOl, lamotrigine, or S-PBN was administered at the time points indicated. MK-S01 was administered at a dose of 5 mg/kg i. p., lamotrigine was administered orally at a dose of 16 mg/kg, and S-PBN was administered at a dose of 300 mg/kg i.p. Since anesthesia induced hypothermia may produce neuroprotection, the body temperature of the an imals was maintained at 37.soC in an incubator during the period of anesthesia (3 to 4 h).
Animals were sacrificed at 7 days by decapitation and the brains were quickly removed and placed in ice-cold 0.9% saline solution. Brains were sectioned at 2-mm in tervals in a brain mold. Slices were placed posterior side down in 2% 2,3,5-triphenyltetrazolium chloride (TTC; Al drich). The slices were stained in the dark at room tem perature for 30 min and then removed and placed in 4% paraformaldehyde, pH 7.3. Lesions (noted by pale stain ing) were evaluated on the posterior surface of each sec tion using an image analysis system by an' experienced investigator blinded to the experimental conditions. Lactate levels were assayed in vivo using both single voxel spectroscopy of the striatum repetition time (TR)/ echo time (TEL 2,0001136 [PRESS; ms] or two dimensional chemical shift imaging as described earlier (Brouillet et aI., 1993) . Diffusion-weighted imaging was performed using a spin echo sequence (TRITE, 2,500/50 ms) with � = 40 ms and 8 = 12 ms and gradients of 3.S G/cm (x,y,z) . All data were collected with a 4.7-T magnet using a birdcage volume coil. To assess the earliest lac tate and diffusion-weighted changes in the striatum, in jections of malonate were performed in four animals in the magnet using an implanted, nonmagnetic catheter (R. T. Matthews et aI., unpublished results). Serial spec troscopic and/or diffusion-weighted imaging were then commenced immediately.
Data are expressed as mean ± SD. Statistical compar isons were made using one-way analysis of variance fol lowed by Fisher protected least significant difference post hoc test to compare group means.
RESULTS
After striatal injections of 3 f1mol malonate there was a rapid increase in lactate production as as sayed by magnetic resonance imaging (MRI) spec troscopy ( Fig. 1 ). Diffusion-weighted images taken at 45 min after injection of malonate showed diffu sion-weighted changes in the striatum (n = 2). We examined whether treatment with the spin trap S-PBN at different time points can attenuate striatal lesions produced by 3 f1mol of malonate. We found previously that three doses of 100 mg / kg S-PBN administered sequentially 1 h before and 2 h and 5 h after injections of malonate produced sig nificantly better protection than a single dose of 100 mg/kg S-PBN (Schulz et aI., 1995) . We therefore examined whether a single dose of 300 mg / kg S-PBN was as efficacious as three doses of 100 mg/ kg S-PBN (n = 8 or 9 per group). Compared to controls (30.5 ± 9.5 mm 3 ), a single dose of 300 mg / kg S-PBN administered 1 h before the striatal injection of malonate protected against striatal lesions as well as three sequential doses of 100 mg / kg S-PBN (17.0 ± 9.2 mm 3 , p < 0.01; and 20.3 ± 9.9 mm 3 , p < 0.05).
Treatment with 300 mg / kg S-PBN 1 h before or 1, 2, 3, or 6 h after the striatal injections of malonate significantly attenuated the lesion volumes (Fig. 2) .
Treatment with 300 mg / kg S-PBN at 9 h (p < 0.11), 12 h (p < 0.08), and 18 h (p < 0.22) after injections of malonate showed some protection; however, it was not statistically significant. Treatment with S-PBN at 24 h did not show any protection.
Treatment with 5 mg / kg MK-801 produced signif icant protection against malonate lesions when ad ministered 1 h before and 1 h after surgery (Fig. 3) . Protection observed when the drug was adminis tered at 2 h was not significant (p < 0.12). Lamo trigine (16 mg/kg) significantly attenuated striatal le sions when administered 1 h before injection of mal onate (Fig. 4) . However, there was no protection when lamotrigine was administered at later time points.
DISCUSSION
A critical issue in the treatment of stroke and a number of other acute neurologic injuries such as brain trauma is the therapeutic time window for ad ministration of neuroprotective agents. The thera peutic time window refers to the time interval fol lowing the acute insult during which an agent can be administered and still exert neuroprotective effects. The duration of this therapeutic time window is as yet unclear. The time window for therapeutic effi cacy may vary depending on the animal model. The time window of efficacy for the NMDA antagonist MK-801 following excitotoxic lesions in the stria tum is 2-J h for depletions of -y-aminobutyric acid (Foster et aI., 1988; Bakker and Foster, 1991; Mas sieu et aI., 1993) . In focal ischemic models, MK-801 was effective when administered 1-2 h after induc tion of the lesion (Park et aI., 1988; Hatfield et aI., 1992) . Glutamate release inhibitors such as BW 619C89 show significant neuroprotecti ve effects when administered 1 h after focal ischemic lesions, whereas after delay to 2 h it was ineffective (Smith et aI., 1993) . A more recent study demonstrated ef ficacy with a delay to 2 h after the ischemic insult, but not at 4 h after occlusion (Swan and Leach, 
1994
). Studies using the non-NMDA receptor antag onist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F) quinoxaline showed efficacy at 60 to 90 min follow ing focal ischemic insults (Buchan et aI., 1991; Xue et aI., 1994) . Similarly, the non-NMDA receptor GYKI-52466 showed efficacy when administered 1 h after a focal ischemic lesion (Smith and Meldrum, 1992) .
Free radical scavengers show efficacy in both fo cal and global models of cerebral ischemia (Park and Hall, 1994) . Free radical spin traps are com pounds that react with free radicals to form more stable adducts (Oliver et aI., 1990; Knecht and Ma son, 1993) and that show efficacy in both focal and global models of cerebral ischemia (Phillis and Clough-Helfman, 1990; Yue et aI., 1992; Cao and Phillis, 1994) . Nitrone-based spin traps penetrate the brain readily at high concentrations (Cheng et aI., 1993) . We found that they attenuate striatal le sions produced by malonate (Schulz et aI., 1995) . They attenuate free radical generation induced by malonate and free radical production produced by ischemia-reperfusion in rats (Sen and Phillis, 1993; Schulz et aI., 1995) . These results indicate that the efficacy of spin traps is very likely due to a free radical scavenging effect.
Recent studies suggested that administration of the free radical spin trap phenyl-N-tert-butyl nitrone could exert neuroprotection when adminis tered as long as 3 h (Zhao et aI., 1994) or 12 h (Cao and Phillis, 1994) after occlu ' sion in a focal model of ischemia in rats. These results therefore show that delayed administration of a putative free radical scavenger may have a markedly enhanced thera peutic time window compared to NMDA antago nists, non-NMDA antagonists, and glutamate re lease blockers. The present study was designed to compare directly the therapeutic time window for the NMDA receptor antagonist MK-801, the gluta mate release inhibitor lamotrigine, and the free rad ical scavenger S-PBN at differing time points fol lowing striatal injection of malonate, which pro duces moderate energy depletion, similar to the penumbra of focal ischemic lesions (Henshaw et al., 1994) . Lamotrigine given orally was effective only when administered before malonate injections. De layed administration of MK-801 was effective at 1 h, consistent with prior studies of both excitotoxic and focal ischemic lesions. In contrast, administra tion of the free radical spin trap S-PBN showed a markedly increased therapeutic window of 6 h, with a trend toward neuroprotection at 9 and 12 h. After striatal injections of malonate, we found an early increase in lactate production and early changes in diffusion-weighted imaging using MRI techniques. The time course of these changes is comparable with results obtained after occlusion of the middle cerebral artery (Gyngell et aI., 1994) , showing that the evolution of lesions produced by malonate is not delayed compared to models of fo cal cerebral ischemia. Therefore, the protection ob served after delayed treatment in our model of his totoxic hypoxia does not depend on a delayed evo lution of the lesion.
These studies therefore provide further evidence that the therapeutic window for treatment with a free radical scavenger is markedly increased com pared to both NMDA antagonists and glutamate re lease inhibitors. This result is consistent with the results of Cao and Phillis (1994) in a focal ischemic model in rats. The results have significant implica tions for the treatment of ischemia in humans. A critical determinant in clinical treatment of stroke is the ability to administer a compound within a ther apeutic window following the acute insult during which the compound may still have neuroprotective effects. Frequently, stroke patients are not seen for up to 6 h after the ischemic insult. The availability of an agent that could be administered at a time point between 6 and 12 h after the initial insult and still have therapeutic efficacy would therefore have a major advantage in the treatment of stroke. The present results suggest that certain free radical scavengers have an improved therapeutic window compared with glutamate receptor antagonists and glutamate release inhibitors, which could be a ther apeutic advantage in the treatment of clinical stroke patients.
